ASPO Abstracts
The potential for metformin to reduce obesity-associated breast cancer risk
Category: Lifestyles Behavior, Energy Balance & Chemoprevention, Lifestyles Behavior, Energy Balance & Chemoprevention
Conference Year: 2018
Abstract Body:
Purpose of the study: To determine the potential effects of metformin on recognized and putative markers of breast cancer risk in women with elements of metabolic syndrome. Statement of methods: We are currently conducting a Phase-II double blind, placebo-controlled clinical trial to study the effect of metformin on obesity-associated breast cancer risk in overweight and obese premenopausal women with metabolic disturbances. Patients who meet the inclusion criteria are randomized to receive metformin 850 mg BID or placebo for 12 months. Our primary endpoint is to monitor breast density through fat- water MRI. Our secondary endpoints include evaluating metabolic changes in serum insulin levels, insulin-like growth factor (IGF)-1 to insulin-like growth factor binding protein (IGFBP)-3 ratio, IGF-2 levels, leptin to adiponectin ratio, waist circumference, and body weight. Summary of Results: Analysis is on going for the association between breast density and metabolic disorders. Our patient population offers us the unique opportunity to study the efficacy of metformin in Hispanic women compared to non-Hispanic women. 35 percent of our total patient population identify as Hispanic. In addition to this, 50 percent of our study population has at least 2 elements of metabolic syndrome, and the remaining 50 percent have 3 elements or more. The baseline characteristics of our patients, on average, are 39.5 years old, have a BMI of 37.8 kg/m2, and a waist circumference of 110.8 cm. Statement of Conclusions: As of November 2017, we have consented 235 women. 84 were ineligible, 4 are pending agent intervention, and 147 have been randomized and started intervention. We are expected to complete the trial in November 2018. Due to the rising rate of obesity, we believe that this trial will have an overwhelming impact in public health especially in minority populations where obesity-induced breast cancer continues to grow. Considering the challenges that many minority populations face, metformin can be used as a safe pharmacological alternative to women who are at risk for obesity-induced breast cancer. Our study will offer the opportunity for metformin to modulate metabolic markers that increase breast cancer risk in Hispanic women.
Keywords: Breast Cancer Metformin Obesity